Influenza A vaccines - Takeda

Drug Profile

Influenza A vaccines - Takeda

Alternative Names: BLB-750; Cell cultured influenza vaccine H5N1 TAKEDA 1mL; Cell cultured influenza vaccine H5N1 TAKEDA 5ml; Cell cultured influenza vaccine prototype TAKEDA 1mL; Cell cultured influenza vaccine prototype TAKEDA 5ml; Pandemic influenza vaccines - Takeda/Ology Bioservices

Latest Information Update: 22 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Class Influenza A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Influenza A virus H5N1 subtype
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H5N1 subtype; Influenza A virus infections

Most Recent Events

  • 14 Dec 2017 Takeda initiates enrolment in a post-marketing phase IV trial for Influenza infections (In volunteers) in Japan (NCT03370289)
  • 07 Dec 2017 Takeda plans a post-marketing phase IV study of influenza A vaccine in healthy volunteers (JapicCTI-173797)
  • 07 Dec 2017 Launched for Influenza-A virus H5N1 subtype (Prevention) in Japan (Parenteral) before December 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top